Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immuno-PET and Targeted α-Therapy Using Anti-Glypican-1 Antibody Labeled with 89Zr or 211At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma.
Watabe T, Kabayama K, Naka S, Yamamoto R, Kaneda K, Serada S, Ooe K, Toyoshima A, Wang Y, Haba H, Kurimoto K, Kobayashi T, Shimosegawa E, Tomiyama N, Fukase K, Naka T. Watabe T, et al. Among authors: serada s. J Nucl Med. 2023 Dec 1;64(12):1949-1955. doi: 10.2967/jnumed.123.266313. J Nucl Med. 2023. PMID: 37827841 Free PMC article.
Extracellular aaRSs drive autoimmune and inflammatory responses in rheumatoid arthritis via the release of cytokines and PAD4.
Kimura A, Takagi T, Thamamongood T, Sakamoto S, Ito T, Seki I, Okamoto M, Aono H, Serada S, Naka T, Imataka H, Miyake K, Ueda T, Miyanokoshi M, Wakasugi K, Iwamoto N, Ohmagari N, Iguchi T, Nitta T, Takayanagi H, Yamashita H, Kaneko H, Tsuchiya H, Fujio K, Handa H, Suzuki H. Kimura A, et al. Among authors: serada s. Ann Rheum Dis. 2023 Sep;82(9):1153-1161. doi: 10.1136/ard-2023-224055. Epub 2023 Jul 2. Ann Rheum Dis. 2023. PMID: 37400117
Nano-particulate Toll-like Receptor 9 Agonist Potentiates the Antitumor Activity of Anti-Glypican-1 Antibody.
Saito Y, Takahashi T, Hiramatsu K, Serada S, Fujimoto M, Ohkawara T, Sugase T, Nishigaki T, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, Nakajima K, Yamasaki M, Ishii KJ, Eguchi H, Doki Y, Naka T. Saito Y, et al. Among authors: serada s. Anticancer Res. 2023 Jun;43(6):2425-2432. doi: 10.21873/anticanres.16410. Anticancer Res. 2023. PMID: 37247902
Combination of pimitespib (TAS-116) with sunitinib is an effective therapy for imatinib-resistant gastrointestinal stromal tumors.
Teranishi R, Takahashi T, Obata Y, Nishida T, Ohkubo S, Kazuno H, Saito Y, Serada S, Fujimoto M, Kurokawa Y, Saito T, Yamamoto K, Yamashita K, Tanaka K, Makino T, Nakajima K, Hirota S, Naka T, Eguchi H, Doki Y. Teranishi R, et al. Among authors: serada s. Int J Cancer. 2023 Jun 15;152(12):2580-2593. doi: 10.1002/ijc.34461. Epub 2023 Feb 21. Int J Cancer. 2023. PMID: 36752576
Lipolysis-stimulated lipoprotein receptor-targeted antibody-drug conjugate demonstrates potent antitumor activity against epithelial ovarian cancer.
Kanda M, Serada S, Hiramatsu K, Funauchi M, Obata K, Nakagawa S, Ohkawara T, Murata O, Fujimoto M, Chiwaki F, Sasaki H, Ueda Y, Kimura T, Naka T. Kanda M, et al. Among authors: serada s. Neoplasia. 2023 Jan;35:100853. doi: 10.1016/j.neo.2022.100853. Epub 2022 Nov 19. Neoplasia. 2023. PMID: 36413881 Free PMC article.
124 results